Pharma BD Deal Intelligence
AZ paid ~$575M for a respiratory bundle, kept the one good asset (Daliresp) until it went generic, and sold the other two brands off as non-core within 2-3 years for $350M.
Full analysis, sources & comparables →The agreement with Takeda complements our respiratory business, one of our three main therapy areas, supports our return to growth and will be immediately…
BioWorld characterized the $575M deal as AZ 'sewing up' global Daliresp rights, consolidating control of the only approved oral PDE4 inhibitor for COPD.
AZ characterized the deal as 'accretive to its 2016 earnings,' strengthening its respiratory franchise and complementing its severe COPD portfolio; 200 Takeda…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca acquired Takeda's core respiratory business including expanded global rights to roflumilast (Daliresp/Daxas), the only approved oral PDE4 inhibitor for COPD, for $575M. Closed 2016.
AZ paid ~$575M for a respiratory bundle, kept the one good asset (Daliresp) until it went generic, and sold the other two brands off as non-core within 2-3 years for $350M.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Takeda Pharmaceutical Company Limited (core respiratory business) (this deal) | 2015 | $575M | 41 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2015 deals · AstraZeneca PLC deals · Respiratory deals